Hereditary Angioedema Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION
Hereditary Angioedema is a rare disorder characterized by recurrent episodes of severe swelling in body parts like limbs, face, intestinal tract or airway. Minor trauma or stress may trigger an attack but swelling often occurs without a known trigger.

MARKET DYNAMICS
The Hereditary Angioedema market is anticipated to grow in the forecast, owing to the factors such as rise in hereditary angioedema attacks, increasing R&D initiatives by the manufacturers, presence of promising drug pipeline, and approval of novel therapies by the regulatory agencies. Nevertheless, lack of awareness regarding the disease, and high cost of the drugs are expected to restrict the market growth during the forecast period.

MARKET SCOPE
The "Global Hereditary Angioedema Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Hereditary Angioedema market with detailed market segmentation by Drugs, Route of Administration, Distribution Channel and geography. The global Hereditary Angioedema market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Hereditary Angioedema market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Hereditary Angioedema market is segmented on the basis of drugs, route of administration and distribution channel. Based on drugs the market is segmented into c1 esterase inhibitor, kallikrein inhibitor, bradykinin receptor, attenuated androgens, and others. Based on route of administration the market is segmented into subcutaneous, intravenous, and oral. Based on distribution channel the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Hereditary Angioedema market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Hereditary Angioedema market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Hereditary Angioedema market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Hereditary Angioedema market in these regions.

Hereditary Angioedema Market Report Analysis

Hereditary Angioedema Market

• 
  CAGR (2023 - 2031)

  XX%
• Market Size 2023
  US$ XX Million
• Market Size 2031
  US$ XX Million

Report Coverage

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope

• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis

• Industry landscape and competition analysis & recent developments
• Detailed company profiles

• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

• BIOCRYST PHARMACEUTICALS, INC
• CSL
• Ionis Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp
• Pharming Group N. V.
• Sanofi N. V.
• Shire plc.
• Teva Pharmaceutical Industries, Ltd.
• Attune Pharmaceuticals

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

By Drugs

• C1 Esterase Inhibitor
• Kallikrein Inhibitor
• Bradykinin Receptor
• Attenuated Androgens

By Route of Administration

• Subcutaneous
• Intravenous
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

MARKET PLAYERS
The reports cover key developments in the Hereditary Angioedema market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Hereditary Angioedema market are anticipated to lucrative growth opportunities in the future with the rising demand for Hereditary Angioedema market in the global market. Below mentioned is the list of few companies engaged in the Hereditary Angioedema market.

The report also includes the profiles of Hereditary Angioedema market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

• BIOCRYST PHARMACEUTICALS, INC
• CSL
• Ionis Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp
• Pharming Group N.V.
• Sanofi N.V.
• Shire plc.
• Teva Pharmaceutical Industries, Ltd.
• Attune Pharmaceuticals
• KalVista Pharmaceuticals, Inc

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Hereditary Angioedema Market Report Scope